Literature DB >> 3930247

Intravenous administration of a thrombolytic agent is the only realistic therapeutic approach in evolving myocardial infarction.

M Verstraete.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3930247     DOI: 10.1093/oxfordjournals.eurheartj.a061906

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  7 in total

Review 1.  Back to the future: so what will fibrinolytic therapy offer your patients with myocardial infarction?

Authors:  J R Mitchell
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-12

Review 2.  Thrombolysis. An approach still on the move.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 3.  Coronary thrombolysis.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1987-04

4.  Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  W S Hillis; R S Hornung; K J Hogg; N Hockings; J M Burns; F G Dunn
Journal:  Drugs       Date:  1987       Impact factor: 9.546

5.  Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.

Authors:  L Kaspar; R Karnik; E Sehnal; P Zajicek; B Ziegler; J Slany
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.

Authors:  D G Julian; L S Borthwick; D Reid; K P Jennings; R J Wainwright; J C Rodger; D Wood; W S Phillips
Journal:  Drugs       Date:  1987       Impact factor: 9.546

7.  A history of streptokinase use in acute myocardial infarction.

Authors:  Nikhil Sikri; Amit Bardia
Journal:  Tex Heart Inst J       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.